The Specialized Histopathology Core was first approved and funded through the CCSG mechanism in 2005. The Core delivers services in a timely fashion and provides the geographically dispersed Cancer Center members with appropriate access to pathology consultative and interpretive services. There are two performance sites: Longwood (which is within minutes of six of the member institutions) and MGH, based at Massachusetts General Hospital. These two locations have enabled the Core to continue to grow and improve service delivery by increasing overall capacity, space and affiliated professional expertise. A full understanding of cancer pathogenesis and response to therapies requires access to technologies and professional expertise that allow cancer cells and biomarkers to be analyzed in situ. The Specialized Histopathology Services (SHP) Core meets this need by providing technical and professional pathology services to Dana-Farber/Harvard Cancer Center (DF/HCC) investigators conducting research with experimental organisms (e.g., rodents, fish, and monkeys) or human tissues. This facility also assists with experimental design and data interpretation. Director(s): Jon Aster, MD, PhD(BMW), Anat Stemmer-Rachamimov, MD(MGH) Category: 4.06 (Human Tissue Acquisition &Pathology/Histology) Management: Joint (Cancer Center and Institutional).

Public Health Relevance

The facility contributes to the scientific mission of the Cancer Center by supporting a wide spectrum of cancer-relevant research, from basic studies on pathogenic mechanisms in cancer to translational research focused on the development of new tests for biomarkers that stratify patients and direct therapy.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Chen, Yi-Bin; Batchelor, Tracy; Li, Shuli et al. (2015) Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer 121:226-33
Waldron, Levi; Haibe-Kains, Benjamin; Culhane, Aedín C et al. (2014) Comparative meta-analysis of prognostic gene signatures for late-stage ovarian cancer. J Natl Cancer Inst 106:
Yilmazel, Bahar; Hu, Yanhui; Sigoillot, Frederic et al. (2014) Online GESS: prediction of miRNA-like off-target effects in large-scale RNAi screen data by seed region analysis. BMC Bioinformatics 15:192
Mazzola, Emanuele; Chipman, Jonathan; Cheng, Su-Chun et al. (2014) Recent BRCAPRO upgrades significantly improve calibration. Cancer Epidemiol Biomarkers Prev 23:1689-95
Zhao, Sihai Dave; Parmigiani, Giovanni; Huttenhower, Curtis et al. (2014) Más-o-menos: a simple sign averaging method for discrimination in genomic data analysis. Bioinformatics 30:3062-9
Parkhitko, Andrey A; Priolo, Carmen; Coloff, Jonathan L et al. (2014) Autophagy-dependent metabolic reprogramming sensitizes TSC2-deficient cells to the antimetabolite 6-aminonicotinamide. Mol Cancer Res 12:48-57
Cheng, Long; Desai, Jigar; Miranda, Carlos J et al. (2014) Human CFEOM1 mutations attenuate KIF21A autoinhibition and cause oculomotor axon stalling. Neuron 82:334-49
Akbay, Esra A; Moslehi, Javid; Christensen, Camilla L et al. (2014) D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. Genes Dev 28:479-90
Brunner, Andrew M; Blonquist, Traci M; Sadrzadeh, Hossein et al. (2014) Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: a SEER database analysis. Leuk Res 38:773-80
Karamichos, D; Hutcheon, A E K; Rich, C B et al. (2014) In vitro model suggests oxidative stress involved in keratoconus disease. Sci Rep 4:4608

Showing the most recent 10 out of 177 publications